ABCL
AbCellera Biologics Inc.
Company Overview
| Mkt Cap | $972.40M | Price | $3.42 |
| Volume | 2.17M | Change | +3.48% |
| P/E Ratio | -- | Open | $3.50 |
| Revenue | -- | Prev Close | $3.30 |
| Net Income | -- | 52W Range | $1.89 - $6.52 |
| Div Yield | N/A | Target | $9.17 |
| Overall | 30 | Value | -- |
| Quality | -- | Technical | 30 |
No chart data available
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Latest News
AbCellera Biologics (ABCL) Receives a Buy from Truist Financial
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABCL | $3.42 | +3.5% | 2.17M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get AbCellera Biologics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW